Crossmark

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination

Crossref DOI link: https://doi.org/10.1186/s40425-019-0634-9

Published Online: 2019-06-25

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Grapin, Mathieu

Richard, Corentin

Limagne, Emeric

Boidot, Romain

Morgand, Véronique

Bertaut, Aurélie

Derangere, Valentin

Laurent, Pierre-Antoine

Thibaudin, Marion

Fumet, Jean David

Crehange, Gilles

Ghiringhelli, François

Mirjolet, Céline https://orcid.org/0000-0003-0047-9421
License Information

Text and Data Mining valid from 2019-06-25
More Information

Article History

Received: 1 February 2019

Accepted: 10 June 2019

First Online: 25 June 2019

Ethics approval

: Before experimentation, the small animal ethics committee (University of Burgundy) and the French Ministry of Higher Education and Research validated the project (APAFIS authorization number: 8235; 10/18/2017).

: Not applicable.

: The authors declare that they have no competing interests.